Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 11/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | PSEN1 | P49768 | 2/20 | 0.34 |
| ▸ | PSEN2 | P49810 | 2/20 | 0.34 |
| ▸ | APH1B | Q8WW43 | 2/20 | 0.34 |
| ▸ | NCSTN | Q92542 | 2/20 | 0.34 |
| ▸ | APH1A | Q96BI3 | 2/20 | 0.34 |
| ▸ | PSENEN | Q9NZ42 | 2/20 | 0.34 |
| ▸ | MMP13 | P45452 | 1/20 | 0.34 |
| ▸ | PDE4A | P27815 | 1/20 | 0.33 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.33 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.33 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.33 |
| ▸ | BMP1 | P13497 | 1/20 | 0.32 |
| ▸ | CCR5 | P51681 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | TGM2 | P21980 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27685734 | 0.93 | ALDH1A1 (0.35) | GPR119ALDH1A1LMNATSHRPSEN1 | |
| SCHEMBL7744031 | 0.86 | CCR5 (0.41) | GPR119ALDH1A1PDE4APDE4BPDE4C | |
| SCHEMBL10128793 | 0.86 | GPR119 (0.41) | GPR119ALDH1A1LMNATSHRPSEN1 | |
| SCHEMBL6258706 | 0.85 | L3MBTL1 (0.43) | ALDH1A1LMNATSHRTGM2 | |
| SCHEMBL2778449 | 0.85 | L3MBTL1 (0.43) | ALDH1A1LMNATSHRTGM2 | |
| SCHEMBL760418 | 0.80 | MEN1 (0.37) | ALDH1A1TGM2 | |
| SCHEMBL8051176 | 0.70 | PSEN1 (0.40) | GPR119ALDH1A1PSEN1PSEN2APH1B | |
| SCHEMBL13405090 | 0.65 | PSEN1 (0.38) | GPR119ALDH1A1PSEN1PSEN2APH1B | |
| SCHEMBL8054683 | 0.65 | PSEN1 (0.38) | GPR119ALDH1A1PSEN1PSEN2APH1B | |
| SCHEMBL28677708 | 0.65 | JAK2 (0.46) | GPR119ALDH1A1PDE4APDE4BPDE4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2064177-B1 | PROTEASE INHIBITORS | TAIMED BIOLOGICS INC (TW) | 2017-04-05 | — | — | EP | disclosed |
| EP-2165709-B1 | Pharmaceutical compositions comprising a lysine based compound and an HIV antiviral or antiretroviral agent | AMBRILIA BIOPHARMA INC (CA) | 2016-03-16 | — | — | EP | disclosed |
| EP-1877091-B1 | METHOD FOR IMPROVING PHARMACOKINETICS OF PROTEASE INHIBITORS AND PROTEASE INHIBITOR PRECURSORS | TAIMED BIOLOG INC (TW) | 2015-03-25 | — | — | EP | disclosed |
| US-8742158-B2 | Protease inhibitors | TaiMed Biologies, Inc. (TW) | 2014-06-03 | — | — | US | disclosed |
| US-8742158-B2 | Protease inhibitors | TaiMed Biologies, Inc. (TW) | 2014-06-03 | — | — | US | disclosed |
| US-8580995-B2 | Lysine-based prodrugs of aspartyl protease inhibitors and processes for their preparation | TAIMED BIOLOGICS, INC. (TW) | 2013-11-12 | — | — | US | disclosed |
| US-8580995-B2 | Lysine-based prodrugs of aspartyl protease inhibitors and processes for their preparation | TAIMED BIOLOGICS, INC. (TW) | 2013-11-12 | — | — | US | disclosed |
| US-20130158261-A1 | PROTEASE INHIBITORS | TAIMED BIOLOGICS, INC. (TW) | 2013-06-20 | — | — | US | disclosed |
| US-20130158261-A1 | PROTEASE INHIBITORS | TAIMED BIOLOGICS, INC. (TW) | 2013-06-20 | — | — | US | disclosed |
| US-8410300-B2 | Protease inhibitors | TAIMED BIOLOGICS, INC. (TW) | 2013-04-02 | — | — | US | disclosed |
| US-20080269172-A1 | Lysine based compounds | TAIMED BIOLOGICS, INC. (TW) | 2008-10-30 | — | — | US | disclosed |
| US-20080269172-A1 | Lysine based compounds | TAIMED BIOLOGICS, INC. (TW) | 2008-10-30 | — | — | US | disclosed |
| EP-1971615-A1 | LYSME-BASED PRODRUGS OF ASPARTYL PROTEASE INHIBITORS AND PROCESSES FOR THEIR PREPARATION | Ambrilia Biopharma Inc. (CA) | 2008-09-24 | — | — | EP | disclosed |
| US-7388008-B2 | Lysine based compounds | AMBRILIA BIOPHARMA INC. (CA) | 2008-06-17 | — | — | US | disclosed |
| US-7388008-B2 | Lysine based compounds | AMBRILIA BIOPHARMA INC. (CA) | 2008-06-17 | — | — | US | disclosed |
| WO-2008023273-A2 | METHOD FOR IMPROVING PHARMACOKINETICS | AMBRILIA BIOPHARMA INC. (US) | 2008-02-28 | — | — | WO | disclosed |
| EP-1877091-A1 | METHOD FOR IMPROVING PHARMACOKINETICS OF PROTEASE INHIBITORS AND PROTEASE INHIBITOR PRECURSORS | Ambrilia Biopharma Inc. (CA) | 2008-01-16 | — | — | EP | disclosed |
| WO-2007062526-A1 | LYSINE-BASED PRODRUGS OF ASPARTYL PROTEASE INHIBITORS AND PROCESSES FOR THEIR PREPARATION | AMBRILIA BIOPHARMA INC. (CA) | 2007-06-07 | — | — | WO | disclosed |
| WO-2006114001-A1 | METHOD FOR IMPROVING PHARMACOKINETICS OF PROTEASE INHIBITORS AND PROTEASE INHIBITOR PRECURSORS | AMBRILIA BIOPHARMA INC. (CA) | 2006-11-02 | — | — | WO | disclosed |
| US-20060025592-A1 | Lysine based compounds | TAIMED BIOLOGICS, INC. (TW) | 2006-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060025592-A1 | Lysine based compounds | DOT1L, H1-2, H1-0 | GPR119 2183/4885ALDH1A1 1740/4885LMNA 1679/4885 |
| US-20080269172-A1 | Lysine based compounds | DOT1L, H1-2, H1-0 | GPR119 2183/4885ALDH1A1 1740/4885LMNA 1679/4885 |
| US-20130158261-A1 | PROTEASE INHIBITORS | PREP, CTRL, CTRB1 | GPR119 3306/4885ALDH1A1 2832/4885LMNA 2671/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.